Additionally, check point inhibition‐based therapies targeting PD1‐PD‐L1 interactions have a durable response rate of 20%–50% in metastatic melanoma,80 potentially due to acquired resistance by loss of HLA class‐I.81, 82. This evidence concerns the gene CD274 and metastatic melanoma.